This article discusses peptides as research compounds. It is not medical advice.
A clinician I spoke with recently described the challenge of measuring visceral fat loss in patients whose total body weight barely changes. That observation frames a growing research question: can certain peptides reduce abdominal obesity even when the scale does not move much? This article discusses peptides as research compounds. It is not medical advice.
AOD-9604 and semaglutide are two compounds frequently examined in metabolic research. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes and, at a different dose, for chronic weight management. AOD-9604 is a modified fragment of human growth hormone (hGH) originally developed to target fat metabolism without the growth-promoting effects of full hGH. Both have appeared in studies related to visceral adipose tissue, but their mechanisms and evidence bases differ substantially.
This article reviews published research on AOD-9604 and semaglutide for visceral fat reduction. It does not recommend personal use, suggest dosages, or compare them as interchangeable medications. Instead, it maps what researchers have observed, what remains unknown, and how to read the data.
What researchers would want to see in a head-to-head trial
A rigorous comparison would need a randomized controlled trial with direct measurement of visceral adipose tissue. The gold standard is magnetic resonance imaging (MRI) or computed tomography (CT) at a single slice, typically L4-L5. Secondary endpoints would include liver fat fraction, inflammatory markers, and insulin sensitivity. Participants would need matched baseline characteristics: age, sex, body mass index, and baseline visceral fat area.
No such head-to-head trial exists for AOD-9604 and semaglutide. The closest published work comes from separate studies with different designs, populations, and endpoints. A 2021 review of GLP-1 receptor agonists noted that semaglutide consistently reduces visceral fat in trials, but the effect size varies widely depending on baseline obesity and diabetes status. AOD-9604 has far less clinical data. Most human studies are small, short, and industry-funded.
Researchers would also want to see dose-response curves for both compounds. Semaglutide's weight-loss dosing is well established from the STEP trials, but its visceral fat effects are usually reported as secondary outcomes. AOD-9604 has no approved dosing for any indication, and published studies used oral or injectable forms at varying frequencies. That heterogeneity makes cross-study comparison unreliable.
What the published research actually shows
Semaglutide has the stronger evidence base for visceral fat reduction. A 2022 analysis of the STEP 1 trial used MRI in a subset of participants and found significant reductions in visceral adipose tissue compared with placebo. The mean change was approximately 20% from baseline after 68 weeks. A separate 2023 study in people with type 2 diabetes reported similar findings, with visceral fat loss exceeding subcutaneous fat loss in relative terms. Those results align with the known physiology: GLP-1 receptor activation reduces appetite and energy intake, and weight loss from any cause tends to mobilize visceral fat first.
AOD-9604 has a different story. Early animal studies in the 1990s suggested that the peptide could stimulate lipolysis in adipose tissue without affecting blood glucose or growth. A 2003 human trial tested oral AOD-9604 in obese adults over 12 weeks and found no significant weight loss compared with placebo. A later 2006 study using a higher oral dose also failed to show meaningful body weight reduction. However, some researchers noted that AOD-9604 might still affect fat distribution even without total weight loss. A 2019 review of growth hormone fragments pointed to unpublished or small pilot data suggesting reduced abdominal fat in specific subgroups, but the evidence remains weak and inconsistent.
The contrast is stark. Semaglutide has multiple large, randomized, placebo-controlled trials with imaging endpoints. AOD-9604 has a handful of small trials, most of which failed on their primary endpoint of total body weight. No published study has directly measured visceral fat with MRI or CT in humans taking AOD-9604. That absence is not proof of ineffectiveness, but it means any claim about AOD-9604 reducing visceral fat is speculative.
Secondary compounds complicate the picture. CJC-1295 and hexarelin are growth hormone secretagogues that increase endogenous growth hormone pulses. Some researchers hypothesize that combining AOD-9604 with a secretagogue might enhance lipolysis, but no controlled human trial has tested that combination for visceral fat. Retatrutide and tirzepatide are newer multi-receptor agonists with even stronger weight-loss effects than semaglutide in early trials. A 2023 phase 2 trial of retatrutide reported dose-dependent reductions in liver fat and visceral adipose tissue, but the drug is not yet approved. Tirzepatide has similar imaging data from its SURPASS program. These compounds may eventually shift the research conversation away from AOD-9604 entirely.
What is missing from the literature
The most obvious gap is a direct comparison. No trial has randomized participants to AOD-9604 versus semaglutide with visceral fat as the primary outcome. Even a non-inferiority design would be informative, but none has been registered. A search of ClinicalTrials.gov in early 2025 shows no active or completed study with that design.
A second gap is long-term safety data for AOD-9604. Semaglutide has years of post-marketing surveillance and a known adverse event profile, including gastrointestinal effects and rare cases of pancreatitis. AOD-9604 has almost no long-term human safety data. The compound was briefly investigated by a pharmaceutical company in the 2000s but development was discontinued. Any researcher considering AOD-9604 must acknowledge that the safety database is essentially empty beyond short-term trials.
A third gap is the mechanism. Semaglutide reduces visceral fat primarily through negative energy balance, though some data suggest direct effects on adipose tissue inflammation. AOD-9604 is proposed to act directly on adipocytes, mimicking a region of growth hormone that stimulates lipolysis. But that mechanism has never been convincingly demonstrated in humans. A 2022 review of peptide-based obesity treatments noted that AOD-9604's mechanism remains unproven outside cell culture and rodent models.
Finally, regulatory status matters. Semaglutide is FDA-approved for specific indications. AOD-9604 is not approved for any medical use in the United States. It is sold as a research chemical and has been the subject of FDA warning letters to compounding pharmacies and peptide vendors. A 2023 warning letter cited a company for marketing AOD-9604 as a weight-loss drug without approval. That regulatory context shapes how researchers can obtain and study the compound.
How to read the evidence without overreaching
When evaluating any peptide for visceral fat reduction, start with the endpoint. Total body weight is not the same as visceral adipose tissue. A compound can reduce visceral fat without changing total weight, and vice versa. Semaglutide trials that report only body weight may understate or overstate visceral effects depending on the population. AOD-9604 trials that failed on body weight may still have had unmeasured effects on fat distribution, but that remains unknown.
Next, check the imaging method. Bioelectrical impedance analysis (BIA) is less accurate than MRI or CT for visceral fat. Some older AOD-9604 studies used skinfold thickness or waist circumference, which are poor proxies for visceral adipose tissue. Semaglutide's STEP trials used MRI in a subset, which is more reliable. Always ask whether the study measured visceral fat directly or inferred it from anthropometrics.
Also consider the comparator. Placebo-controlled trials tell you whether a compound works better than nothing. Active-controlled trials tell you whether it works better than an existing option. AOD-9604 has only placebo-controlled data, and those trials mostly failed. Semaglutide has placebo-controlled and active-controlled data, including comparisons with other GLP-1 agonists. The absence of active-controlled trials for AOD-9604 is a major limitation.
Finally, watch for publication bias. Small negative trials are less likely to be published than small positive ones. AOD-9604's published record is mostly negative, which suggests either a true lack of effect or a publication landscape that suppressed positive findings. Either way, the available literature does not support strong conclusions.
The honest answer for researchers
Based on published evidence, semaglutide has demonstrated visceral fat reduction in multiple randomized trials with imaging endpoints. AOD-9604 has not. That does not mean AOD-9604 is useless; it means the research base is too thin to make any claim. A researcher interested in visceral fat would be better served by studying semaglutide, tirzepatide, or retatrutide, all of which have at least some imaging data. AOD-9604 remains a compound of historical interest and occasional regulatory scrutiny, but not a proven tool for visceral fat reduction.
For those following peptide regulatory news, the contrast is instructive. Semaglutide's path from diabetes drug to obesity treatment involved large trials, FDA review, and post-marketing surveillance. AOD-9604 has never cleared any of those hurdles. The FDA has issued multiple warning letters to companies selling AOD-9604 as a fat-loss product. A 2024 enforcement action against a peptide vendor cited AOD-9604 among unapproved new drugs. That regulatory history should temper any enthusiasm based on preclinical data.
This article discusses peptides as research compounds. It is not medical advice. If you are pregnant, nursing, or under medical treatment, consult your physician before considering any compound covered in this article.
Common questions
Does AOD-9604 reduce visceral fat in humans?
No published human trial has measured visceral fat directly with MRI or CT in people taking AOD-9604. Early trials focused on total body weight and mostly failed. A 2003 study of oral AOD-9604 found no significant weight loss after 12 weeks. A 2006 follow-up also failed. Some researchers speculate that AOD-9604 might affect fat distribution without changing total weight, but that hypothesis remains untested in controlled human studies. The compound's mechanism, proposed as direct stimulation of lipolysis in adipocytes, has been shown in cell culture and rodents but not confirmed in humans. Until imaging-based trials are conducted, any claim about AOD-9604 reducing visceral fat is unsupported by evidence.
How much visceral fat does semaglutide reduce?
In the STEP 1 trial, a subset of participants underwent MRI. Those receiving semaglutide 2.4 mg weekly had a mean reduction in visceral adipose tissue of about 20% from baseline after 68 weeks, compared with a smaller reduction in the placebo group. A separate 2023 study in type 2 diabetes reported similar relative reductions. The absolute amount varies with baseline visceral fat, sex, and age. Semaglutide's effect on visceral fat is generally proportional to overall weight loss, but some data suggest visceral fat is mobilized preferentially. The clinical significance of that preferential effect is still debated.
Is AOD-9604 FDA approved for weight loss?
No. AOD-9604 is not approved by the FDA for any medical use. It is not a prescription drug, an over-the-counter product, or a dietary supplement. The compound was investigated in clinical trials in the early 2000s but development was discontinued. Since then, the FDA has issued warning letters to companies marketing AOD-9604 as a weight-loss or fat-burning product. In 2023 and 2024, enforcement actions targeted peptide vendors selling AOD-9604 as an unapproved new drug. Researchers must obtain the compound through legitimate chemical suppliers and cannot administer it to humans without an Investigational New Drug application.
Can AOD-9604 be combined with semaglutide for visceral fat?
No published clinical trial has tested that combination. The two compounds have different mechanisms: semaglutide reduces energy intake through GLP-1 receptor activation, while AOD-9604 is proposed to act directly on fat cells. In theory, they could be additive, but that is speculation. The safety of combining them is unknown. Semaglutide has known gastrointestinal side effects, and AOD-9604's long-term safety profile is essentially empty. A researcher considering such a combination would need to justify it with preclinical data and proceed under strict regulatory oversight. No such study has been registered.
What about CJC-1295 or hexarelin for visceral fat?
CJC-1295 and hexarelin are growth hormone secretagogues. They increase endogenous growth hormone pulses, which can promote lipolysis. Some body recomposition studies have used them in combination with other peptides, but no large randomized trial has measured visceral fat as a primary outcome. A 2022 review of growth hormone secretagogues noted that most human data come from small, short-term studies in growth hormone deficiency or aging. The relevance to visceral fat in otherwise healthy obese adults is unclear. Researchers interested in this area should look for trials with imaging endpoints, not just body composition scales.
This article discusses peptides as research compounds. It is not medical advice.